Original Article
European Journal of Clinical Nutrition (2008) 62, 155–161; doi:10.1038/sj.ejcn.1602748; published online 28 March 2007
Soy isoflavone intake inhibits bone resorption and stimulates bone formation in menopausal women: meta-analysis of randomized controlled trials
Contributors: P-YW and RK contributed to the design of this article. D-FM and L-QQ contributed to the collection of data and statistical analysis, and have also contributed equally to the work. All authors read and approved this article.
D-F Ma1,2, L-Q Qin3, P-Y Wang1 and R Katoh2
- 1Department of Social Medicine and Health Education, School of Public Health, Peking University, Beijing, China
- 2Department of Human Pathology, Interdisciplinary Graduate School of Medicine and Engineering, University of Yamanashi, Yamanashi, Japan
- 3Department of Nutrition and Food Hygiene, School of Radiation Medicine and Public Health, Soochow University, Suzhou, China
Correspondence: Professor P-Y Wang, Department of Social Medicine and Health Education, School of Public Health, Peking University, Xueyuan Road 38, Haidian District, Beijing, China. E-mail: G06DA006@ccn.yamanashi.ac.jp
Received 25 October 2006; Revised 14 February 2007; Accepted 19 February 2007; Published online 28 March 2007.
Abstract
Objective:
To clarify the effects of isoflavone intake on bone resorption and bone formation.
Methods:
We identified randomized controlled trials related to urinary deoxypyridinoline (Dpyr, a bone resorption marker) and serum bone-specific alkaline phosphatase (BAP, a bone formation marker) listed on MEDLINE (January 1966–April 2006), the Cochrane Controlled Trials Register, EMBASE (1985–January 2006), Science Citation Index and PUBMED (updated till April 2006).
Results:
Nine studies with a total of 432 subjects were selected for meta-analysis. The urinary Dpyr concentration in subjects who consumed isoflavones decreased significantly by -2.08 nmol/mmol (95% confidence interval (CI): -3.82 to -0.34 nmol/mmol) in comparison with that in subjects who did not consume isoflavones. Isoflavone intake vs placebo intake significantly increased serum BAP by 1.48 
g/l (95% CI: 0.22–2.75 g/l). Decreases in the urinary Dpyr concentration with isoflavone intake of <90 mg/day and with treatment lasting less than 12 weeks were -2.34 nmol/mmol (95% CI: -4.46 to -0.22 nmol/mmol) and -2.03 nmol/mmol (95% CI: -3.20 to -0.85 nmol/mmol), respectively.
Conclusions:
Isoflavone intervention significantly inhibits bone resorption and stimulates bone formation. These favorable effects occur even if <90 mg/day of isoflavones are consumed or the intervention lasts less than 12 weeks.
Keywords:
soy, isoflavone, osteoporosis, bone metabolism, deoxypyridinoline, bone-specific alkaline phosphatase
MORE ARTICLES LIKE THIS
These links to content published by NPG are automatically generated
RESEARCH
Laboratory Investigation Article Response
Urinary phytoestrogen concentrations in the U.S. population (1999?2000)
Journal of Exposure Analysis and Environmental Epidemiology Research Article
Urinary phytoestrogen concentrations in the U.S. population (1999?2000)
Journal of Exposure Analysis and Environmental Epidemiology Research Article
European Journal of Clinical Nutrition Original Article
